MiR-126: a novel route for natalizumab action?
Treatment, therapies and management:
MicroRNAs (miRNAs) are involved in post-transcriptional regulation of gene expression, exerting their effects on different aspects of immunity. A previous study showed differential miR-126 expression in CD4+T cells of untreated RRMS patients.
This study looks at the expression of miR-126 in 24 natalizumab-treated patients, 12 untreated patients and 12 healthy controls. The results showed miR-126 was down-regulated in patients on natalizumab treatment, while miR-126 was up-regulated during relapse in patients on natalizumab treatment.
It was also shown that miR-126 expression was associated with expression of POU2AF1. POU2AF1 is a regulator of Spi-B, which binds to the promoter region of JC virus (JCV). Inhibition experiments showed a link between the expression of miR-126 and POU2AF1/Spi-B. These results provide further insight into the mechanism of action of natalizumab, which helps us better understand the effects of natalizumab, as well as it side effect profile.
Meira M, Sievers C
: Mult Scler. 2014 Mar 5. [Epub ahead of print]
Read the abstract